RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Akero Therapeutics Stock

Akero Therapeutics ROCE 2025

Akero Therapeutics ROCE

-0.38

Ticker

AKRO

ISIN

US00973Y1082

WKN

A2PLNP

In 2025, Akero Therapeutics's return on capital employed (ROCE) was -0.38, a 17.83% increase from the -0.32 ROCE in the previous year.

Akero Therapeutics Aktienanalyse

What does Akero Therapeutics do?

Akero Therapeutics Inc is an advanced biotherapy company focused on the development and commercialization of medications to improve patient health. The company was founded in 2017 by five experienced pharmaceutical experts: Andrew Cheng, Timothy Lu, David D. Kirn, Scott Freeman, and Stuart Lockhart. Akero Therapeutics Inc is headquartered in Belmont, California, USA. The business model of Akero Therapeutics Inc is based on targeted biological therapy aiming to address unmet medical needs in various disease areas. The idea is to reduce the risk of diseases such as diabetes, chronic liver diseases, and metabolic disorders and improve the quality of life for patients through the development of innovative biological agents. Akero Therapeutics is dedicated to combating these diseases with groundbreaking therapeutic approaches. The company offers various divisions including product development, research and development, and commercial. Product development at Akero Therapeutics encompasses the discovery, development, clinical testing, and efficacy assessment of new biological agents. The research division continuously works on identifying new target molecules to develop innovative approaches in disease therapy. The commercial division of Akero Therapeutics is responsible for developing an appropriate marketing strategy to bring the biological agents to market readiness and to patients. One of the most well-known products of Akero Therapeutics is the medication Efruxifermin (EFX). It is a protein molecule developed for the treatment of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease characterized by the accumulation of fat in the liver without the patient consuming alcohol during the day. Fatty liver disease is a growing public health issue and one of the most common liver diseases worldwide. Akero Therapeutics has developed an effective medication, EFX, which effectively reduces liver fat content. Another product currently in the clinical research phase at Akero Therapeutics is AKR-001. It is a medication for the treatment of patients with lipid metabolism disorders, including hypertriglyceridemia and homozygous familial hypercholesterolemia. Lipid metabolism disorders are characterized by high levels of triglycerides and cholesterol in the blood and increase a patient's risk for cardiovascular diseases. In summary, Akero Therapeutics is a clinical biotherapy company dedicated to the development of treatments for various chronic diseases. The company combines innovative research with strong entrepreneurial capabilities to explore, develop, and bring new biological agents to the market for disease therapy. Akero Therapeutics is on track to establish a strong presence in the biopharmaceutical industry and has the potential to improve the lives of millions of patients worldwide. Akero Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Akero Therapeutics's Return on Capital Employed (ROCE)

Akero Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Akero Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Akero Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Akero Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Akero Therapeutics stock

What is the ROCE (Return on Capital Employed) of Akero Therapeutics this year?

The ROCE of Akero Therapeutics is -0.38 undefined this year.

How has the ROCE (Return on Capital Employed) of Akero Therapeutics developed compared to the previous year?

The ROCE of Akero Therapeutics has increased by 17.83% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Akero Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Akero Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Akero Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Akero Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Akero Therapeutics impact the company?

An increase in the ROCE of Akero Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Akero Therapeutics affect the company?

A decrease in ROCE of Akero Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Akero Therapeutics?

Some factors that can affect Akero Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Akero Therapeutics so important for investors?

The ROCE of Akero Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Akero Therapeutics take to improve the ROCE?

To improve the ROCE, Akero Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Akero Therapeutics pay?

Over the past 12 months, Akero Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akero Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Akero Therapeutics?

The current dividend yield of Akero Therapeutics is .

When does Akero Therapeutics pay dividends?

Akero Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akero Therapeutics?

Akero Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Akero Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akero Therapeutics located?

Akero Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akero Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akero Therapeutics from 8/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/5/2025.

When did Akero Therapeutics pay the last dividend?

The last dividend was paid out on 8/5/2025.

What was the dividend of Akero Therapeutics in the year 2024?

In the year 2024, Akero Therapeutics distributed 0 USD as dividends.

In which currency does Akero Therapeutics pay out the dividend?

The dividends of Akero Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Akero Therapeutics

Our stock analysis for Akero Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akero Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.